Old drug, new hope for rare skin cancer?
NCT ID NCT01556035
First seen May 14, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, repeating this cycle for up to a year. The main goal was to see how many patients had their tumors shrink or disappear after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HM Hôpital Nord
Marseille, 13915, France
-
AP-HP Groupe hospitalier Bichat - Claude Bernard
Paris, 75877, France
-
AP-HP Groupe hospitalier Cochin
Paris, 75679, France
-
AP-HP Hôpital Ambroise Paré
Boulogne-Billancourt, 92104, France
-
AP-HP Hôpital Avicenne
Bobigny, 93009, France
-
AP-HP Hôpital Henri Mondor
Créteil, 94010, France
-
AP-HP Hôpital Tenon
Paris, 75970, France
-
AP-HP- Hôpital Saint Louis
Paris, 75475, France
-
CHRU de Montpellier Hôpital Saint-Eloi
Montpellier, 34295, France
-
CHU Amiens, Hôpital Sud
Amiens, 80054, France
-
CHU Besançon, Hôpital Saint-Jacques
Besançon, 25030, France
-
CHU Lyon Sud
Pierre-Bénite, 69450, France
-
CHU de Bordeaux Hôpital du Haut Lévèque
Pessac, 33604, France
-
CHU de Clermont-Ferrand, Estaing
Clermont-Ferrand, 63003, France
-
CHU de Dijon, Le Bocage
Dijon, 21079, France
-
CHU de Grenoble
Grenoble, 38043, France
-
CHU de Lille Hôpital Claude Huriez
Lille, 59037, France
-
CHU de Nantes, Hôtel Dieu
Nantes, 44093, France
-
CHU de Nice Groupe hospitalier l'Archet
Nice, 06202, France
-
CHU de Reims, Hôpital Robert Debré
Reims, 51092, France
-
CHU de Rouen, Hôpital Charles Nicolle
Rouen, 76031, France
-
CHU de Toulouse Hôpital Larrey
Toulouse, 31059, France
-
CHU de Tours- Hôpital Trousseau
Tours, 37044, France
-
Centre Léon Bérard
Lyon, 69373, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide (Revlimid)
What this could lead to
If it works, this could offer a new treatment option for people with this rare skin lymphoma that has come back after initial therapy.
What could go wrong
This is a small, early-phase trial with only 19 participants, so results may not apply broadly. Lenalidomide can cause side effects like low blood counts and fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.